Anti-Cancer Agents Work in Antagonism with Inhibitors of HSP 72
Journal Title: Diseases & Research - Year 2023, Vol 3, Issue 2
Abstract
Purpose The heat shock genes are evidenced to be active in the migration and are major promoters of several human malignancies. The inclined expression of HSP 72 proteins play an inevitable role in protecting cancer cells from apoptosis, promoting cellular progression, which is one of the factors for reduced sensitivity towards conventional therapies. Thisin-vitrostudy used Acute Myeloid Leukaemia (AML) cell lines U937 and Chronic Myeloid Leukaemia (CML) cell line K562 to evaluate the effect of Pifithrin chloride (PES-Cl) - an inhibitor of HSP 72 protein activity as single agent and in combination with chemotherapeutic Bortezomib in order to elucidate the activity of these molecules in cellular apoptosis. Methods The cells were treated for initial response with PES-CL for 1h and a potential enhancement with another chemotherapeutic Bortezomib other over a 24 h time course and wise verse. The cytotoxic effects of the treatment were analysed by MTS assay and the combination index for the drug combinations tested were analysed for synergy, additive or antagonism using Compusyn software (Compusyn, Inc). Apoptosis was evaluated by Annexin V/PI assay. HSP 72 and BCL-2 expressions were analyzed by flow-cytometer. Results The MTS cell viability assay depicted no sign of enhancement of cytotoxicity by either of the PES-Cl/ Bortezomib drug combinations tested, but reflected antagonistic effects in U937 and K562 cell lines, exhibiting a CI of >1, explicitly indicating antagonism. Although both cell lines were responsive and showed antagonism, U937 were chosen for further investigations. The U937 cells showed apoptosis and no necrosis was found at any level of the investigation by Annexin V/PI assay. The cells exhibited HSP 72 inhibition for single and combination drug treatments. The results noted a high BCL-2 expression in U937 cells with the drug combinations of PES-Cl and Bortezomib disregard of the mode of administration followed. However, the highest expression was observed in cells exposed to PES-Cl initially and subsequently with Bortezomib treatment. Conclusion This present study is the first to investigate the potential activity of PES-Cl an HSP 72 inhibitor in combination with Bortezomib in leukemia cancers. And it is interesting to note the antagonism exhibited by the drug combinations. However, prospective studies are critical in elucidating explicitly the mode of action of these agents, to potentially overcome resistance to canonic chemotherapy and improve the therapeutic potential of leukemic treatments.
Authors and Affiliations
Muneera Mohamed Sahib, Paolo Marsico, John H. H. Williams
Keywords
Related Articles
- EP ID EP740183
- DOI 10.54457/DR.202302004
- Views 48
- Downloads 0
Primary Extramedullary Plasmacytoma of the Kidney: A Case Report and Literature Review
Extramedullary plasmacytomas (EMPs) usually occur in the upper respiratory tract, the occurrence in the kidney is extremely rare. The present study reported a case of primary renal plasmacytoma in a 46-year-old male pati...
Application of Immunoenhancing Radiotherapy in Treating Unresectable Intrahepatic Cholangiocarcinoma: A Case Report
Unresectable intrahepatic cholangiocarcinoma currently lacks standard treatment methods. This report presents a case where PET/CT scans showed a subcapsular mass in the right posterior lobe of the liver measuring 6.2 cm...
Significance of Liquid Biopsy Containing Circulating Tumor DNA (ctDNA) Analysis for Evaluation and Management of Metastatic Cancer
According to the GLOBOCAN 2020 data from WHO, nearly 10 million deaths took place due to cancer thus, cancer became a leading cause of death all over the world. The most common cancer are breast cancer, lung cancer, colo...
Salvage Therapy with Gilteritinib Plus Venetoclax for FLT3-ITD-Positive AML: A Case Report and Literature Review
FMS-like tyrosine kinase 3 (FLT3) mutations occur in around 30% of patients in acute myeloid leukemia (AML), and are generally associated with unfavorable outcomes. Gilteritinib is a highly specific second-generation cla...
Hepatic Paragonimiasis: A Case Report and Literature Review
Paragonimiasis is a parasitic disease caused by paragnonimus, which primarily caused infection in the lung, and ectopic infection was less common. Ectopic paragonimiasis are more likely to be misdiagnosed as malignancy o...